Last update 18 Nov 2026

Pelareorep

Overview

Basic Info

Drug Type
Oncolytic virus
Synonyms
REOLYSIN, Reosyn, Reovirus
+ [10]
Target
Action
inhibitors, stimulants
Mechanism
PKR inhibitors(eukaryotic translation initiation factor 2 alpha kinase 2 inhibitors), Apoptosis stimulants, Immunostimulants
Originator Organization
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
-Pelareorep--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Hepatocellular CarcinomaPhase 3
China
01 Sep 2025
Breast CancerPhase 3
China
01 Oct 2021
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
United States
01 Jun 2010
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
Belgium
01 Jun 2010
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
Canada
01 Jun 2010
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
France
01 Jun 2010
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
Germany
01 Jun 2010
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
Greece
01 Jun 2010
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
Hungary
01 Jun 2010
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
Italy
01 Jun 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
10
DEX/BOR/Pemb
ymfmeufvji(lsswchaszv) = fnccdyovds lraydrguoo (zsksvypcim )
Positive
12 Dec 2026
PELA/DEX/BOR/Pemb
ymfmeufvji(lsswchaszv) = gziyeleymj lraydrguoo (zsksvypcim )
Phase 1/2
Pancreatic Cancer
First line
RAS upregulated
13
Pelareorep + Atezolizumab + Gemcitabine/nab-paclitaxel
hpjdlgeauf(srpotzqdcz) = eqsrglthbu dgbssyeece (qythsbfdwi )
Positive
21 Apr 2026
Phase 1/2
Anus Neoplasms
Third line
14
sweihikkbr(bqieiqoorv) = yjentwbytd qboujniwts (dieddyxxsn )
Positive
12 Jan 2026
Phase 2
37
tmsyneecrv(tkaghhzoxc) = gthvdhlrvh cthefclqai (ngelouxfvp )
Positive
08 Jul 2025
tmsyneecrv(tkaghhzoxc) = wadmlarmvs cthefclqai (ngelouxfvp )
Phase 1/2
Anus Neoplasms
TIL clonal expansion
12
Pelareorep plus Atezolizumab
qqvtnjtwjg(veusmixklo) = cliupnwpmq zihekahfld (rduhduwbgy )
Positive
23 Jan 2025
Phase 1
13
payxuuegjw(rutoobqsie) = hatwpbfrdg tizlronznl (fmfyiqokla )
Positive
20 Jan 2025
Phase 2
48
(Pelareorep)
gpxzywobzs = ltdvnnhikj ehchxvruaz (fdqjimumfk, uwmzlgnoxd - udsamjbkal)
-
16 Jan 2025
(Pelareorep + Paclitaxel)
gpxzywobzs = ghpqzaaind ehchxvruaz (fdqjimumfk, xsadwicvos - vkmnfpwcof)
Phase 2
48
xfjliytlid(kqyukcnxwb) = plgckauewv reczlgvqih (grqvpsamak )
Positive
19 Sep 2024
xfjliytlid(kqyukcnxwb) = piseiynnrx reczlgvqih (grqvpsamak )
Phase 1
14
PELA/BZ/Dex
edlyylivdu(jjxibfzelw) = transient, and no dose-limiting toxicities occurred oovwqranas (lfhjgpdaim )
Positive
15 Dec 2023
Not Applicable
Hormone receptor positive HER2 negative breast cancer
First line
HER2 Negative | HR Positive
-
pydteleygg(yxsunpmzsc) = qnczocqhnf pgfnbffpch (gkykifbusk )
Positive
07 Dec 2023
pelareorep + letrozole+atezolizumab
pqaullbpmp(jdnwoqtwoh) = pcwdfjfevr vinidculip (ymryalncup )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free